Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5966)
All Articles published online
|
Publishing Process of This Article
|
Jun 21, 2014 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ridruejo E. Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir. World J Gastroenterol 2014; 20(23): 7169-7180 [PMID: 24966587 DOI: 10.3748/wjg.v20.i23.7169] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i23/7169.htm |
| Number | Citing Articles |
| 1 |
E. L. Krasavtsev, E. I. Romanova. CHANGES OF THE INCIDENCE STRUCTURE OF PATIENTS WITH CHRONIC VIRAL FORMS OF HEPATITIS B AND ASSESSMENT OF EFFICACY OF ITS DIFFERENT TREATMENT SCHEMES. Health and Ecology Issues 2016; (1): 27 doi: 10.51523/2708-6011.2016-13-1-6
|
| 2 |
Yan Xu, Yong-Gui Zhang, Xu Wang, Wen-Qian Qi, Shao-You Qin, Zhen-Hua Liu, Jian Jiao, Jiang-Bin Wang. Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis. World Journal of Gastroenterology 2015; 21(25): 7869-7876 doi: 10.3748/wjg.v21.i25.7869
|
| 3 |
Kuo‐Chih Tseng, Chih‐Wei Tseng, Tsai‐Yuan Hsieh, Cheng‐Yuan Peng, Chih‐Lin Lin, Tung‐Hung Su, Tai‐Chung Tseng, Hans Hsienhong Lin, Chia‐Chi Wang, Jia‐Horng Kao. Efficacy of entecavir therapy for hepatitis B e‐antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues. Hepatology Research 2016; 46(7): 642 doi: 10.1111/hepr.12600
|
| 4 |
Raquel Scherer de Fraga, Victor Van Vaisberg, Luiz Cláudio Alfaia Mendes, Flair José Carrilho, Suzane Kioko Ono. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. Journal of Gastroenterology 2020; 55(5): 496 doi: 10.1007/s00535-020-01680-0
|
| 5 |
Bircan Kayaaslan, Rahmet Guner. Adverse effects of oral antiviral therapy in chronic hepatitis B. World Journal of Hepatology 2017; 9(5): 227-241 doi: 10.4254/wjh.v9.i5.227
|
| 6 |
Jae-Jun Shim, In Hwan Oh, Sang Bae Kim, Jung Wook Kim, Chang Kyun Lee, Jae Young Jang, Ju-Seog Lee, Byung-Ho Kim. Predictive Value of Antiviral Effects in the Development of Hepatocellular Carcinoma in the General Korean Population with Chronic Hepatitis B. Gut and Liver 2016; 10(6): 962 doi: 10.5009/gnl15426
|
| 7 |
J. Truong, B. Shadbolt, M. Ooi, S. Chitturi, G. Kaye, G. C. Farrell, N. C. Teoh. Week 4 viral load predicts long‐term suppression of hepatitis B virus DNA during antiviral therapy: improving hepatitis B treatment in the real world. Internal Medicine Journal 2017; 47(1): 50 doi: 10.1111/imj.13244
|
| 8 |
Yi-Cheng Chen, Yun-Fan Liaw. Pharmacotherapeutic options for hepatitis B. Expert Opinion on Pharmacotherapy 2016; 17(3): 355 doi: 10.1517/14656566.2016.1118056
|
| 9 |
Lin Fan, Kwame Owusu‐Edusei, Sarah F. Schillie, Trudy V. Murphy. Cost‐effectiveness of active‐passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection. Hepatology 2016; 63(5): 1471 doi: 10.1002/hep.28310
|
| 10 |
Camila V Pereira, Cristiane Valle Tovo, Thiago K Grossmann, Henrique Mirenda, Bruna B Dal-Pupo, Paulo RL de Almeida, Angelo A de Mattos. Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil. Memórias do Instituto Oswaldo Cruz 2016; 111(4): 252 doi: 10.1590/0074-02760150390
|
| 11 |
Xuefeng Ma, Shousheng Liu, Mengke Wang, Yifen Wang, Shuixian Du, Yongning Xin, Shiying Xuan. Tenofovir Alafenamide Fumarate, Tenofovir Disoproxil Fumarate and Entecavir: Which is the Most Effective Drug for Chronic Hepatitis B? A Systematic Review and Meta-analysis. Journal of Clinical and Translational Hepatology 2021; 0(000): 000 doi: 10.14218/JCTH.2020.00164
|
| 12 |
Bircan Kayaaslan, Esragul Akinci, Alpay Ari, Zeliha Kocak Tufan, Saygın Nayman Alpat, Ozgur Gunal, Selma Tosun, Rahmet Guner, Fehmi Tabak. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients. Clinics and Research in Hepatology and Gastroenterology 2018; 42(1): 40 doi: 10.1016/j.clinre.2017.06.008
|
| 13 |
Leanne C Nye, Nicola Gray, Myra McClure, Marta Boffit, Elaine Holmes, Robert S Plumb, Ian D Wilson. Identification of A Novel Human Circulating Metabolite of Tenofovir Disoproxil Fumarate with LC–MS/MS. Bioanalysis 2015; 7(6): 643 doi: 10.4155/bio.14.300
|
| 14 |
Shan‐Ru Zuo, Xiao‐Cong Zuo, Chun‐Jiang Wang, Yu‐Tao Ma, Hao‐Ye Zhang, Zuo‐Jun Li, Li‐Ying Song, Zhen‐Zhen Deng, Shi‐Kun Liu. A meta‐analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection. The Journal of Clinical Pharmacology 2015; 55(3): 288 doi: 10.1002/jcph.409
|
| 15 |
Fatemeh Bakhshizadeh, Soheila Hekmat, Maryam Keshvari, Seyed Moayed Alavian, Ehsan Mostafavi, Hossein Keivani, Amin Doosti, Fatemeh Motevalli, Bita Behnava. Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleoside-Analogue Naive Iranian Patients Treated for Chronic Hepatitis B. Hepatitis Monthly 2015; 15(5) doi: 10.5812/hepatmon.15(5)2015.25749
|